Palisade Bio, Inc. (NASDAQ: PALI) has seen an upward revision in its earnings forecast for fiscal year 2025, according to a research report released by Brookline Capital Management on November 12, 2023. Analyst K. Raja now estimates the company will report a loss of $0.18 per share, a significant improvement from the previous projection of $1.55. The consensus estimate for the company’s full-year earnings stands at $12.43 per share.
In addition to the FY2025 estimate, Brookline Capital Management has provided projections for Palisade Bio’s future earnings. The anticipated earnings for the fourth quarter of 2025 are expected to be $0.01 per share, while forecasts for FY2026, FY2027, FY2028, and FY2029 are projected at $0.16, $0.17, $0.20, and $0.25 per share, respectively.
Palisade Bio’s recent quarterly earnings report, released on November 10, 2023, indicated a loss of $0.38 per share, which was below the consensus estimate of $0.32 by $0.06.
Stock Performance and Market Position
On the trading day following the earnings report, shares of Palisade Bio opened at $2.14. The company has a market capitalization of approximately $318.87 million, with a price-to-earnings ratio of -1.01 and a beta of 1.60. Over the past year, the stock has fluctuated, reaching a low of $0.53 and a high of $3.30. The 50-day and 200-day simple moving averages are currently $1.43 and $1.00, respectively.
Institutional Investment Activity
Recent filings indicate that institutional interest in Palisade Bio has increased. Armistice Capital LLC boosted its holdings in the company by 37.4% during the first quarter, as detailed in its latest Form 13F submission to the Securities and Exchange Commission. The firm now owns 144,764 shares, having acquired an additional 39,397 shares during the period, representing about 3.29% of the company with a total value of approximately $99,000. Currently, institutional and hedge fund investors hold about 11.79% of Palisade Bio’s stock.
Palisade Bio, a clinical-stage biopharmaceutical company based in the United States, is focused on developing therapies aimed at preserving the integrity of the intestinal barrier. Its lead candidate, PALI-2108, is a prodrug PDE4 inhibitor that is currently in pre-clinical development for treating inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease. Another candidate, PALI-1908, is an oral, selective PDE4 inhibitor prodrug that is designed to be activated locally in the terminal ileum of Crohn’s disease patients and is currently in the research phase.
For those interested in following the latest developments regarding Palisade Bio and related news, a free daily summary can be obtained by subscribing to MarketBeat’s newsletter.
